Psilmi®
Bringing together clinical expertise, eye-tracking technology and digital biomarker research to explore new possibilities in autism, ADHD, depression, anxiety and beyond.
Built through collaboration
Better tools for neuropsychiatry start with the right clinical questions—and the right partners.
Our approach to Psilmi® is partnership-first. We seek to work with academic, clinical and industry collaborators to identify unmet needs, develop targeted applications and build the evidence required for meaningful clinical use.
Rather than pursuing a single diagnostic label, our ambition is to create a shared foundation for investigating different conditions, overlapping symptoms and individual differences. Each application follows its own path from research question to validation.
From eye-tracking data to meaningful insights
Psilmi® combines eye-tracking measurements with digital biomarker analysis to explore how responses to visual stimuli can inform our understanding of neuropsychiatric conditions.
The aim is to investigate patterns across multiple biomarkers—not rely on one measurement to explain a complex clinical picture. This creates opportunities to study both differences between conditions and features they may share.
Our longer-term goal is to provide objective insights that complement clinical judgment and support more informed decisions about assessment and care.
Shape the next application with us
We welcome partners who bring important questions, specialist expertise or opportunities to translate research into practice.
Collaboration can focus on:
- Clinical needs and study design: defining relevant questions, populations and outcomes.
- Biomarker research: investigating which measurements are informative, reliable and reproducible.
- Application development: exploring specific use cases and how they could fit into clinical workflows.
- Validation and translation: building the evidence needed for potential future clinical and regulatory development.
Psilmi® is co-developed with Uppsala University in Sweden. We invite additional partners to help shape its next stage of development.
Evidence-led development
Promising research is a starting point—not a substitute for clinical validation.
Our partnership strategy places evidence at the centre of development: understanding where an application may add value, testing its limitations and establishing what further research is needed. Potential applications in autism, ADHD, depression and anxiety must each be evaluated for their intended purpose.
Psilmi® is currently available for research and evaluation and is not a cleared medical device.
Join the research beta
Interested in exploring Psilmi® within a research collaboration?
Tell us about your research question, clinical setting or development interests. Together, we can discuss whether the research beta is an appropriate starting point and define the scope, responsibilities and requirements for participation.
Discuss a partnership or research project:
psilmi@stardots.se
Download the beta:
Psilmi blends Ψ (Psi)—the long‑standing symbol of psychology—with Finnish silmä/silmiä (eye/eyes), reflecting both our scientific roots and our measurement focus.
Security & Privacy
- Data ownership: Stays with the site and/or participant per study agreements
- De‑identification & pseudonymization options for exports
- Encryption in transit and at rest (implementation details available under NDA)
- Role‑based access and audit logs for study operations
- Optional offline capture with secure sync when connectivity is available
We support GDPR‑aligned practices and local ethics requirements; implementation specifics are finalized per site.
FAQ
Is Psilmi a medical device?
Not yet. It is currently provided for research use within our beta program. Regulatory submissions are planned.
What outcomes does Psilmi provide today?
Standardized acquisition of ocular physiology under controlled stimuli, with emerging biomarker features; analytical tooling is evolving.
How are participants consented?
Per site protocol and ethics approvals. Psilmi supports de‑identification workflows and data export controls.
Which eye trackers are supported?
We integrate with leading research‑grade systems via SDKs. Contact us for the current validated list, but most of Tobii eye trackers are supported, if the requirement of a minimum of 120 Hz sample rate is met.
Can we run offline?
Yes—offline test sessions with secure synchronization when connectivity returns (optional, configuration‑dependent).
Contact
Stardots AB, Uppsala, Sweden
Daniel Petrini, CEO, daniel.petrini@stardots.se, +46 70‑782 70 01
General inquiries info@stardots.se
Learn more www.stardots.se
Psilmi is co-developed with Uppsala University (Sweden) and aiming in first hand for FDA 510(k) US market clearance. Pilot study from 2024 shows strong diagnostic accuracy. Potential for expansion into more neuropsychiatric conditions.